


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use of~~ A method of treatment of a disorder mediated by CB<sub>1</sub> receptors comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I):



(I)

wherein:

R<sup>1</sup> is aryl;

R<sup>2</sup> is H, alkyl or aryl; and

R<sup>3</sup> is hydrogen or alkyl;

or a pharmaceutically acceptable salt or prodrug thereof, ~~in the manufacture of a medicament for the treatment of a disorder mediated by CB<sub>1</sub> receptors.~~

2. (Currently Amended) ~~A use method~~ A method according to claim 1 wherein R<sup>1</sup> is a substituted or unsubstituted phenyl or naphthyl.
3. (Currently Amended) ~~A use method~~ A method according to claim 1 ~~or 2~~ wherein R<sup>1</sup> has 1, 2 or 3 substituent groups.
4. (Currently Amended) ~~A use method~~ A method according to claim 1, ~~2 or 3~~ wherein R<sup>1</sup> is chlorophenyl or (trifluoromethyl)phenyl.
5. (Currently Amended) ~~A use method~~ A method according to claim 1, ~~2, 3 or 4~~ wherein R<sup>2</sup> is aryl.

6. (Currently Amended) A ~~use~~method according to ~~any one of claims 1 to 5~~ claim 5 wherein R<sup>3</sup> is alkyl.

7. (Currently Amended) A ~~use~~method according to claim 1 wherein the compound is selected from:

3-(bis(4-chlorophenyl)methoxy)-N-(2-propenyl)azetidine-1-carboxamide; and  
(R)-3-(bis(4-chlorophenyl)methoxy)-N-(2-hydroxypropyl)azetidine-1-carboxamide.

8. (Currently Amended) A ~~use~~method according to ~~any preceding claim 1~~ wherein said medicament comprises the dose further comprises a pharmaceutically acceptable carrier and as active ingredient an effective amount of a compound of formula (I).

9. (Canceled)

10. (Currently Amended) A ~~use or~~method according to ~~any preceding claim 1~~ wherein the disorder is selected from psychosis, schizophrenia, cognitive disorders, attention deficit disorder, to gastrointestinal disorders, smoking cessation, obesity and other eating disorders associated with excessive food intake, and non-insulin dependant diabetes mellitus.

11. (Currently Amended) A ~~use or~~method according to ~~any of claims 1 to 10~~ claim 1 wherein the disorder is obesity.

12. (Currently Amended) A ~~use or~~method according to ~~any of claims 1 to 10~~ claim 1 for smoking cessation.

13. (Currently Amended) A ~~use or~~method according to ~~any of claims 1 to 10~~ claim 1 wherein said disorder is a gastrointestinal disorder.

14. (New) A method according to claim 2 wherein R<sup>1</sup> is a substituted or unsubstituted phenyl or naphthyl.

15. (New) A method according to claim 2 wherein  $R^1$  has 1, 2 or 3 substituent groups.
16. (New) A method according to claim 2 wherein  $R^1$  is chlorophenyl or (trifluoromethyl)phenyl.
17. (New) A method according to claim 1 wherein  $R^2$  is aryl.
18. (New) A method according to claim 7 wherein the disorder is selected from psychosis, schizophrenia, cognitive disorders, attention deficit disorder, to gastrointestinal disorders, smoking cessation, obesity and other eating disorders associated with excessive food intake, and non-insulin dependant diabetes mellitus.
19. (New) A method according to claim 7 wherein the disorder is obesity.
20. (New) A method according to claim 7 for smoking cessation.
21. (New) A method according to claim 7 wherein said disorder is a gastrointestinal disorder.